These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 30101496)

  • 1. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs for Amyotrophic Lateral Sclerosis].
    Ogino M
    Brain Nerve; 2023 May; 75(5):503-506. PubMed ID: 37194520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
    Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
    Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
    Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].
    Kollewe K; Dengler R; Petri S
    Nervenarzt; 2008 Jun; 79(6):653-61. PubMed ID: 18210046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
    Soares P; Silva C; Chavarria D; Silva FSG; Oliveira PJ; Borges F
    Ageing Res Rev; 2023 Jan; 83():101790. PubMed ID: 36402404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.